These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 11241254

  • 1. The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma.
    Sherman EJ, Pfister DG, Ruchlin HS, Rubin DM, Radzyner MH, Kelleher GH, Slovin SF, Kelly WK, Scher HI.
    Cancer; 2001 Feb 15; 91(4):841-53. PubMed ID: 11241254
    [Abstract] [Full Text] [Related]

  • 2. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
    Malmberg I, Persson U, Ask A, Tennvall J, Abrahamsson PA.
    Urology; 1997 Nov 15; 50(5):747-53. PubMed ID: 9372886
    [Abstract] [Full Text] [Related]

  • 3. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ, Hernandez-McClain J, Henary H.
    Am J Clin Oncol; 2008 Dec 15; 31(6):532-8. PubMed ID: 19060583
    [Abstract] [Full Text] [Related]

  • 4. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project).
    Hallert E, Husberg M, Jonsson D, Skogh T.
    Rheumatology (Oxford); 2004 Nov 15; 43(11):1374-82. PubMed ID: 15280570
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
    Ghatnekar O, Alvegård T, Conradi N, Lenhoff S, Mellqvist UH, Persson U, Löthgren M.
    Clin Ther; 2008 Sep 15; 30(9):1704-13. PubMed ID: 18840377
    [Abstract] [Full Text] [Related]

  • 8. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
    Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ.
    J Clin Oncol; 2005 Nov 01; 23(31):7904-10. PubMed ID: 16258090
    [Abstract] [Full Text] [Related]

  • 9. Cumulative cost pattern comparison of prostate cancer treatments.
    Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll PR.
    Cancer; 2007 Feb 01; 109(3):518-27. PubMed ID: 17186528
    [Abstract] [Full Text] [Related]

  • 10. The economic burden of prostate cancer, California, 1998.
    Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X.
    Cancer; 2002 Jun 01; 94(11):2906-13. PubMed ID: 12115378
    [Abstract] [Full Text] [Related]

  • 11. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
    Pether M, Goldenberg SL, Bhagirath K, Gleave M.
    Can J Urol; 2003 Apr 01; 10(2):1809-14. PubMed ID: 12773232
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.